Fibromyalgia Research Studies
The National Fibromyalgia Association (NFA) is pleased to play a role in helping to facilitate research that will bring a better understanding of fibromyalgia (FM) and its symptoms: pain, fatigue, sleep disturbances and cognitive impairment. With the help of people who are living with FM and the people who care for them, we believe that we can find answers that will help improve the quality of life for everyone effected by this painful disorder.
We invite you take part in the following research studies. Please note that the NFA values your privacy and assures your anonymity and confidentiality.
Together we can help improve the quality of life for people with FM and chronic pain!
Researchers are LISTENING… Share With Them!
Fibromyalgia Research Studies
Center Watch/ Clinical Trials Listing Service. CenterWatch delivers critical industry insights to 150,000 life science executives every week through its newsletters, conferences, webinars, books, in-depth market surveys, industry profiles and clinical databases. And millions of patients and caregivers start their search for clinical trials with CenterWatch, with one of the largest clinical trial databases on the internet, CenterWatch iConnect.
National Institutes of Health Clinical Trials
National Institutes of Health Clinical Trials – US National Library of Medicine. The ClinicalTrials.gov Web site provides current information about clinical research studies to patients, their families and caregivers, health care professionals, and the public. Each study record includes a summary of the study protocol, including the purpose, recruitment status, and eligibility criteria. Study locations and specific contact information are listed to assist with enrollment.
Investigators from the University of Michigan in conjunction with the National Fibromyalgia Association have developed a study to understand general knowledge of and attitudes toward the use of psychedelics (psilocybin mushrooms, LSD, DMT, ayahuasca, mescaline) among individuals with chronic pain. The information you provide in the attached survey will help inform physicians, researchers, policymakers and patients about potential benefits and risks of psychedelics as therapeutic agents.
The results of the study will help investigators find improved ways to help you manage your pain, and by participating, you can help share knowledge that will contribute to a better quality of life for people with fibromyalgia and chronic pain. The researchers conducting this study and the institutions involved do not advocate or promote any form of illicit substance use — the aim of this study is to gauge interest about psychedelic treatments and/or sample from individuals who have used psychedelics in the past.
European League Against Rheumatism
Dear FM Community:
The European League Against Rheumatism (EULAR) continues to support a multidisciplinary approach, combining non-medicinal and medicinal treatments, to manage fibromyalgia. Master of Health Informatics student, Linda M. Feshami, BS, RHIT, CRC, CHC, CDIP of the College of St. Scholastica, with the collaboration of the NFA, is conducting research to determine if there is a significant difference in pain levels when a non-medicinal treatment is combined with an existing medicinal treatment.
The study involves a short survey (approximately 10 min). Participants will be asked to rate pain levels at three separate points: 1) before treatment (either medicinal or non-medicinal), 2) during medicinal treatment only, and 3) medicinal combined with non-medicinal using a Likert Scale. Study participants must be at least 18 years of age, diagnosed with fibromyalgia syndrome (FMS) by a health care practitioner, have experienced debilitating/life-altering pain symptoms
due to FMS for a minimum of two years, and have added a non-medication treatment to an existing treatment based on medication alone.
To go to the survey: Click Here. IP addresses will not be collected. Questions regarding the survey may be directed to Linda M. Feshami at email@example.com or 507-273-7764. Thank you for supporting this research.
The NFA and I look forward to receiving your responses and once again, thank you.